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Introduction: Human induced pluripotent stem cells (hiPSCs) have been derived from various somatic cell types.
Granulosa cells, a group of cells which surround oocytes and are obtained from the (normally discarded) retrieved
egg follicles of women undergoing infertility treatment, are a possible cell source for induced pluripotent stem cell
(iPSC) generation. Here, we explored the possibility of using human granulosa cells as a donor cell type for iPSC
reprogramming, and compared granulosa cell-derived iPSCs (iGRAs) with those derived from other cell sources, to
determine the potential ability of iGRA differentiation.
Methods: Granulosa cells were collected from egg follicles retrieved from women undergoing infertility treatment.
After short-term culture, the granulosa cells derived from different patients were mixed in culture, and infected with
retroviruses encoding reprogramming factors. The resulting iPSC clones were selected and subjected to microsatellite
DNA analysis to determine their parental origin. IGRAs were subjected to RT-PCR, immunofluorescence staining, and
in vitro and in vivo differentiation assays to further establish their pluripotent characteristics.
Results: Microsatellite DNA analysis was used to demonstrate that hiPSCs with different parental origins can be
simultaneously reprogrammed by retroviral transfection of a mixed human granulosa cell population obtained from
multiple individuals. The iGRAs resemble human embryonic stem cells (hESCs) in many respects, including
morphological traits, growth requirements, gene and marker expression profiles, and in vitro and in vivo developmental
propensities. We also demonstrate that the iGRAs express low levels of NLRP2, and differentiating iGRAs possess a
biased differentiation potential toward the trophoblastic lineage. Although NLRP2 knockdown in hESCs promotes
trophoblastic differentiation of differentiating hESCs, it does not result in exit from pluripotency. These results imply
that NLRP2 may play a role in regulating the trophoblastic differentiation of human pluripotent stem cells.
Conclusions: These findings provide a means of generating iPSCs from multiple granulosa cell populations with
different parental origins. The ability to generate iPSCs from granulosa cells not only enables modeling of
infertility-associated disease, but also provides a means of identifying potential clinical interventions through
iPSC-based drug screening.* Correspondence: kuohuch@gate.sinica.edu.tw
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Human induced pluripotent stem cells (hiPSCs) are gen-
erated from somatic cells by overexpression of a panel of
transcription factors, including OCT4, SOX2, KLF4, and
c-MYC [1]. The resulting hiPSCs exhibit the typical
characteristics of human embryonic stem cells (hESCs);
not only do they express surface and pluripotency-
related markers, but they are also able to give rise to cell
types representing all three embryonic germ layers, as
demonstrated by both in vitro differentiation and in vivo
teratoma formation analysis. Induced pluripotent stem
cell (iPSC) technology therefore provides an easy and ef-
ficient means of generating embryonic stem cell (ESC)-
like cells from any individual. The availability of iPSCs
circumvents the ethical disputes and immunological
problems arising from the use of hESCs, thereby open-
ing up new possibilities for disease modeling and stem
cell-based therapies.
At the time of writing, fibroblasts are the most com-
mon donor source for iPSC generation; however, a var-
iety of alternative cell types have also been used for the
derivation of iPSC lines, on account of their availability
or ease of reprogramming. One such example is periph-
eral blood cells, which are widely used because of the
ease with which they can be obtained from patients and
because of their ability to be reprogrammed without the
need for extensive cell culture [2,3]. Human keratino-
cytes [4], neural stem cells [5,6], and cord blood CD133+
cells [7] have a higher reprogramming efficiency than
human fibroblasts and/or require fewer transcription
factors for reprogramming; this is believed to be due to
their expression of pluripotent genes, or possession of
an epigenomic regulatory pattern that is closer to ESCs
than that of fibroblasts. Previous studies indicated that
differences between the origins of cell types influence re-
programming efficiency, as well as the in vitro differenti-
ation potential of iPSCs. For example, analysis of early-
passage iPSCs (derived from mouse fibroblasts, and
hematopoietic and myogenic cells) indicated that these
cells possess different transcriptional and epigenetic pro-
files, which results in distinctive in vitro differentiation
potentials [8]. Therefore, it has become apparent that se-
lection of the donor cell type for generation of iPSCs is a
critical issue because the parental cell type affects the ef-
ficiency of reprogramming, the requirements for type
and quality of ectopic transcription factors, the in vitro
and in vivo developmental propensities, and the epigen-
etic memory of the resulting iPSCs.
Human granulosa cells are crucial for the growth and
development of oocytes during ovarian folliculogenesis.
These cells not only secrete the hormones required for
ovulation and endometrial proliferation, but their nor-
mal function is also required for avoiding disorders of
the human ovary, including polycystic ovary syndrome[9], premature ovarian failure [10], and granulosa cell
tumors [11]. Although granulosa cells are important for
female reproduction, the understanding of their involve-
ment in ovarian function and dysfunction is limited,
mostly due to the difficulty in generating a suitable
model for in vitro study. With advances in assisted re-
productive techniques and in vitro culture methods, hu-
man granulosa cells have become available for use in
such studies; granulosa cells can be retrieved from infer-
tile women, and prolonged culture of these cells in vitro
can be achieved by adding leukemia inhibitory factor
[12]. Thus, we explored the possibility of using human
granulosa cells as a donor cell type for iPSC reprogram-
ming, and compared granulosa cell-derived induced
pluripotent stem cells (iGRAs) with those derived from
other cell sources, to determine the potential suitability
of iGRAs for the study of female reproductive disease.
In this study, we demonstrate that hiPSC clones can
be simultaneously generated from human granulosa cells
with different parental origins. Although human iGRAs
resembled hESCs in terms of their pluripotent character-
istics and in vivo/in vitro differentiation potential, iPSCs
derived from granulosa cells exhibited a greater propen-
sity to differentiate to the trophoblast lineage as com-
pared with hESCs and other iPSC lines. In addition, the
expression of NLRP2 was found to be generally lower in
human iGRAs than in other cell lines, and this was con-
firmed to be associated with preferential differentiation
into trophoblasts.
Materials and methods
Ovarian stimulation and collection of human granulosa cells
The ovarian stimulation protocol involved combined use
of short flare-up gonadotropin-releasing hormone agonist
and recombinant follicle-stimulating hormone (225 IU/day
for 10 days, GONAL-f PEN; Merck Serono, Merck
KGaA, Darmstadt, Germany). When at least two folli-
cles reached a size of 18 mm, human chorionic gonado-
tropin (Ovidrel; Merck Serono, Merck KGaA, Darmstadt,
Germany) was used to trigger final maturation of the
oocytes. Transvaginal oocyte retrieval was then per-
formed approximately 35 hours after injection of hu-
man chorionic gonadotropin. Human granulosa cells
were obtained from the pooled follicular fluid aspirates
from patients. Granulosa cells were enriched in accord-
ance with a recently published protocol [13].
Cell culture
Human granulosa cells from three Asian females and fore-
skin fibroblasts from a 28-year-old male were obtained
with written informed consent from tissue donors, in
accordance with the protocol approved by the Research
Ethics Committee of National Taiwan University Hospital
and the Internal Research Board of Academia Sinica.
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grown and expanded in Dulbecco’s modified Eagle’s
medium (Invitrogen, Carlsbad, CA, USA) containing 15%
fetal bovine serum (Invitrogen), 2 mML-glutamine (Invi-
trogen), 0.1 mM nonessential amino acids (Invitrogen),
and 1% penicillin/streptomycin (Invitrogen). Human fol-
licle dermal papilla cells were purchased from PromoCell
Inc. (Heidelberg Germany) and maintained in Human
Follicle Dermal Papilla Cell Growth Medium (PromoCell
Inc.) according to the manufacturer’s protocol. These cells
were subjected to iPSC induction within four passages
after receipt.
The hiPSCs and hESCs, H9 (46, XX; WiCell Research
Institute Inc., Madison, WI, USA) and NTU1 (46, XX;
National Taiwan University and Hospital, Taipei, Taiwan),
were grown on mitotically-inactivated mouse embryonic
fibroblasts in Dulbecco’s modified Eagle’s medium/F12
(Invitrogen) with 20% Knockout Serum Replacement
(Invitrogen), and basic fibroblast growth factor (4 ng/ml;
Sigma, St. Louis, MO, USA). Passage of hiPSCs and hESCs
was performed every 5 to 7 days by manual splitting.
Retroviral infection and iPSC generation
Derivation of human iPSCs was performed as described
previously [14]. All plasmids for generating iPSCs were
purchased from Addgene (Cambridge, MA, USA); these
plasmids included pMXs-hOCT3/4 (Addgene 17217),
pMXs-hSOX2 (Addgene 17218), pMXs-hKLF4 (Addgene
17219), and pMXs-hc-MYC (Addgene 17220).
For granulosa cells, four consecutive transductions were
performed. Six days after the first transduction, fibroblasts
and papilla cells were trypsinized and reseeded at 5 × 104
cells per 100 mm dish on mouse embryonic fibroblast
feeders. Granulosa cells were trypsinized and replated at
1 × 105 cells per 100 mm dish on mouse embryonic fibro-
blast feeders 8 days after the first transduction. On the next
day, the media were replaced with hESC media, as de-
scribed above. Approximately 30 days after transduction,
colonies were picked manually and transferred into 0.5 ml
hESC media in 24-well plates, before being scaled up.
Characterization of human iPSCs
Genomic DNA and RNA were extracted from repro-
grammed clones with the DNeasy Mini Kit and the RNeasy
Mini Kit separately (Qiagen, Hilden, Germany). Integration
of retroviral transgenes was examined by PCR analysis with
specific primers; in addition, the expression of endogenous
genes and viral transgenes (OCT4, SOX2, KLF4, c-MYC,
and other pluripotency genes) of reprogrammed cells
was assessed by RT-PCR with specific primers [1].
Generation of constitutive knockdown hESCs
The shNLRP2 and shLuc constructs were obtained from the
National RNAi Core Facility Platform (National ScienceCouncil, Taipei, Taiwan). The target sequences for shNLRP2
constructs were as follows: shNLRP2-128236, GCTGAAT
CACATAGGAGTTAA; shNLRP2-130989, CCAGGTTAT
GGCTGAGAGATA; and shNLRP2-129801, CTCAGGGA
TAATGAGTTCATT. Lentiviral production and hESC
infection were performed in accordance with a proced-
ure described previously [15].In vitro random and trophoblastic differentiation of iPSCs
and hESCs
The protocols for embryonic body formation and random
differentiation were described previously [16]. Tropho-
blastic differentiation was induced using the protocol of
Xu and colleagues [17], and recombinant human BMP4
(R&D, Minneapolis, MN, USA) was added at a concentra-
tion of 20 ng/ml.RNA isolation, reverse transcription, PCR, and quantitative
PCR
Total RNA was extracted from hESCs, iPSCs, and their
differentiated cells, and then treated with DNase I (Qiagen).
Total RNA was converted to cDNA using the High
Capacity cDNA Reverse Transcriptase Kit (Applied
Biosystems, Foster City, CA, USA). PCR was performed
with the Platinum Taq DNA polymerase kit (Invitrogen)
according to the manufacturer’s instructions. Quantitative
PCR was performed with the SYBR FAST ABI Prism
qPCR Kit (KAPA, Wilmington, MA, USA), and was an-
alyzed with the 7900 real-time PCR system (Applied
Biosystems). Results were normalized using GAPDH,
and analyzed based on the relative quantification (ΔΔ-
Ct method). Primer sequences are shown in Additional
file 1.Immunofluorescence staining, western blot analysis, and
teratoma formation
Immunofluorescence (IF) staining, western blot analysis,
and teratoma formation were performed as described
previously [16]. Primary antibodies against the following
proteins were used in this study: OCT4 (1:200), SSEA4
(1:200), TRA-1-60 (1:200), TG30 (1:200), HESCA-1
(1:200), HESCA-2 (1:200), MAP2 (1:500), CDX2 (1:200),
and EOMES (1:200; Millipore, Temecula, CA, USA),
PAX6 (1:50; DSHB, Iowa City, IA, USA), AFP (1:500;
Dako, Glostrup, Denmark), SOX17 (1:200) and CG-α
(1:500; R&D), GATA4 (1:200) and GATA2 (1:500; Santa
Cruz, Dallas, TX, USA), a-SMA (1:500) and β-actin (1:800;
Sigma), and CG-β (1:500) and NLRP2 (1:1,000; Abcam,
Cambridge, UK). The following secondary antibodies were
used: goat anti-mouse, rabbit Cy3 (1:500; Jackson Immu-
noResearch laboratories, West Grove, PA, USA); and goat
anti-mouse, rabbit 488 (1:200; Invitrogen).
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Genomic DNA was extracted from 13 selected iGRAs,
and identity analysis was performed using the AmpFlSTR
Identifiler kit (Applied Biosystems), according to the
manufacturer’s instructions. Fifteen microsatellite loci
(D8S1179 on chromosome 8, D21S11 at 21q11.2, D7S820
at 7q, CSF1PO at 5q33.3-34 labeled with 6-FAM,
D3S1358 at chromosome 3p, THO1 at 11p15.5, D13S317
at 13q22-31, D16S539 at 16q24-qter, D2S1338 at 2q35-
37.1 labeled with VIC, D19S433 at 19q12-13.1, vWA at
12p12-pter, TPOX at 2p25.3, D18S51 at 18q21.3 labeled
with NED, D5S818 at 5q21-31, and FGA at 4q28 labeled
with PET) and the amelogenin loci on the X (p22.1-22.3)
and Y (p11.2) chromosomes were analyzed.
Microarray analysis
Two micrograms of total RNA purified by Trizol (Invi-
trogen) were used to generate biotin-labeled cRNA
probes, which were hybridized to the Affymetrix Human
Genome U133 plus 2.0 array (Affymetrix, Santa Clara,
CA, USA) by the Affymetrix gene expression service la-
boratory at Academia Sinica (Taipei, Taiwan). Chips
were scanned using the Affymetrix GeneChip Scanner
7G, and expression profiles were analyzed with Gene-
Spring XI software (Agilent, Santa Clara, CA, USA).
Two biological replicates were performed for each cell
line. Raw data were normalized with Robust Multichip
Average, and weakly expressed signals (means <20% of
total samples) were excluded. The raw microarray data are
available through the Gene Expression Omnibus [GEO:
GSE28406, GEO:GSE19964].
Immunoassays of placental hormones
The media from trophoblastic differentiation were col-
lected on days 0, 2, 4, 7, 12, and 14, and were examined
for the presence of β-HCG (IBL international GmbH,
Hamburg, Germany), estradiol, and progesterone (Cayman
Chemical Company, Ann Arbor, MI, USA) using enzyme
immunoassays.
Results
A one-pot method to simultaneously derive iPSC lines
from granulosa cells obtained from multiple donors
To generate iPSCs, we obtained human granulosa cells
from three female donors. Since the granulosa cell popu-
lation of each donor is small, we mixed the cells from
each individual and cultured them together. These cells
were then subjected to retroviral infection with vectors
containing human OCT4, SOX2, KLF4, and c-MYC
cDNA during their early passages (P1 to P4) (Figure 1A,
a). On day 20, around 100 early reprogramming cell col-
onies were detected within the initial 2 × 105 granulosa
cells (Figure 1A,b and Table 1). A total of 30 iPSC clones
were manually picked based on their morphologicaltraits at 30 days post viral infection (Figure 1A,c), and
24 of them were used to successfully establish iPSC lines
(Table 1). Genomic PCR and RT-PCR using primers
specific for the retroviral transcripts [1] were performed
to reveal integration and silencing of exogenic OCT4,
SOX2, KLF4, and c-MYC genes in 10 of the 24 clones
(Figure 1B,a,b). The pluripotent potential of the selected
iPSC lines was further demonstrated by the expression
of endogenous pluripotency-associated genes and hESC
markers (Figure 1B,c,C).
To identify the original donors of the derived iPSC
lines, we performed a DNA microsatellite assay to deter-
mine the parentage of each clone. A total of 15 micro-
satellite loci and one amelogenin locus on the sex
chromosomes were analyzed for each of the selected 13
iGRAs. Such analyses revealed that one donor resulted
in 12 of the 13 iPSC lines, a second donor resulted in a
single line (iGRA6), while the third donor was not repre-
sented in any of the established iPSC lines (Figure 2 and
Additional file 2). These results demonstrate that it is
possible to simultaneously derive multiple iPSC clones
from mixed granulosa cell samples derived from mul-
tiple individuals.
Granulosa cell-derived iPSCs exhibit pluripotent
characteristics both in vitro and in vivo
To investigate their developmental propensity, three
iGRAs (iGRA1, iGRA2, and iGRA7) were subjected to
both in vitro and in vivo differentiation procedures. For
in vitro differentiation, embryonic body was generated to
allow spontaneous differentiation. At around 20 days,
differentiated cells expressing markers of mesoderm
(GATA4 and α-SMA), ectoderm (PAX6 and MAP2), and
endoderm (SOX17 and AFP) were identified by IF stain-
ing (Figure 3A). RT-PCR was used to confirm the IF
staining data, by detecting expression of genes related
to mesoderm (Hand1, cTnI, and GATA4), ectoderm
(PAX6, SOX1, and MAP2), and endoderm (GATA6,
AFP, and HNF4A) in the in vitro differentiated iPSCs at
around day 20 (Figure 3C). In addition, teratoma forma-
tion was assessed to determine developmental potential
in vivo. Combined histological and immunohistochemi-
cal analysis of iGRA-induced teratomas revealed that the
cells had differentiated into cell types representing all
three embryonic germ layers (Figure 3B).
To further explore the differentiation potential of
iGRAs, quantitative PCR was used to quantify the expres-
sion of lineage-specific genes. The expression patterns of
mesoderm, ectoderm, endoderm, and germ cell genes
were not consistent between H9 hESCs, foreskin-derived
iPSCs (iCFB46 and iCFB50), and three iGRA lines with
the same parental origin (Figure 4A and Additional file 3).
The differentiation potential of these pluripotent cell lines
seemed to vary between different iPSC clones. Notably,
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Figure 1 Derivation and characterization of induced pluripotent stem cells derived from human granulosa cells. (A) Reprogramming of
induced pluripotent stem cell (iPSC) lines: (a) parental granulosa cells at early passage (P1), (b) early reprogrammed cell colonies, and (c) human
embryonic stem cell (hESC)-like colonies prior to being manually picked. (B) Genetic analysis of reprogrammed cell lines: (a) genomic PCR was
used to reveal integration of all four retroviral transgenes, and (b) RT-PCR was used to demonstrate inactivation of exogenous viral transgenes
and (c) expression of endogenous pluripotency genes. H9 hESCs (H9) and human granulosa cells (G) were used as controls for PCR and RT-PCR
reactions. (C) Immunofluorescence analysis of pluripotency hESC markers (OCT4, SSEA4, TRA-1-60, TG30, HESCA-1, and HESCA-1) in a representative
human granulosa cell-derived iPSC line (iGRA1). Scale bars = 200 μm (A,a,b,c) and 50 μm (C).
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such as CDX2, EOMES, and ERRB, were higher in the
iGRA clones than in hESCs and foreskin-derived iPSCs
(Figure 4A and Additional file 3). Next, we used antibodies
against trophoblastic antigens (including CDX2 and
EOMES) to perform IF staining on cells (derived from
hESC (H9), hiPSC (iCFB50), and iGRA1, iGRA2, and
iGRA7) undergoing trophoblastic differentiation. Our
quantitative analysis revealed a significantly higher num-
ber of CDX2-positive or EOMES-positive cells for differ-
entiated iGRA1, iGRA2, and iGRA7 cells than for H9 and
iCFB50 cells (Figure 4B,C). These results suggest that
Figure 2 Microsatellite marker analysis for human granulosa cell-derived induced pluripotent stem cells. Four representative induced
pluripotent stem cell clones and four representative microsatellite loci are shown.
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trophoblastic lineages in vitro.
NLRP2 was expressed at low levels in human granulosa
cell-derived iPSCs
The results described above indicate that iGRAs prefer-
entially differentiate towards the trophoblastic lineage;
we proceeded to investigate the possible mechanism
underlining this observation by comparing the global
gene-expression profiles of the parental cells of iPSCs,
hESCs (H9 and NTU1), foreskin-derived iPSCs (iCFB46
and iCFB50), follicle dermal papilla cell-derived iPSCs
(iDPC3 and iDPC4), and iGRA1 and iGRA2 using
cDNA microarray analysis. Pearson correlation analysis
revealed that the transcriptional profiles of all iPSC lines
were similar to those of hESCs, and different from thoseof their parental cells (Additional file 4). Comparison of
the global gene expression patterns for all of the pluripo-
tent stem cell lines revealed that iGRAs clustered more
closely with hESCs than with other lines (Figure 5A).
However, expression levels of NLRP2, a gene required
for preimplantation development of human and mouse
[18,19], were significantly lower in all tested iGRAs than
in hESCs (Figure 5B,C and Additional file 5). Notably,
the expression level of NLRP2 in iPSC parental cells is
low, and is significantly increased after pluripotency repro-
gramming (Figure 5C and Additional file 5). Furthermore,
its expression level decreased significantly in hESCs after
in vitro differentiation (Figure 6B and Additional file 6).
The results obtained with quantitative PCR are consistent
with the microarray data (Additional file 5). Thus, we have
confirmed that iGRAs exhibit relatively low expression of
Figure 3 In vitro and in vivo differentiation of human granulosa cell-derived induced pluripotent stem cells. (A) Immunofluorescence
staining against three germ layer markers in a representative induced pluripotent stem cell line (iGRA1) following in vitro differentiation. (B)
Hematoxylin and eosin staining of teratoma derived from a representative iGRA line (iGRA1). (C) RT-PCR analysis of expression of genes associated
with three germ layers in in vitro differentiated iGRAs. 1, 2 and 7, iGRA1, iGRA2, and iGRA7, respectively. N, RNA transcripts untreated with reverse
transcriptase (no RT control) served as a negative control for genomic DNA contamination. Scale bars = 50 μm (A) and 30 μm (B).
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We therefore hypothesize that the low expression of
NLRP2 may result in the preferential trophoblastic differ-
entiation potential of iGRAs.
Knockdown of NLRP2 expression promotes trophoblastic
differentiation in hESCs
To confirm whether low expression of NLRP2 results
in the preferential trophoblastic differentiation potential
of iGRAs, we used lentiviral-based RNA interference to
specifically knockdown (KD) NLRP2 mRNA in H9 hESCs.
H9 hESCs were transfected with the shLuc control, or
one of three KD NLRP2 variants (−128236, −130989,
and −129801). KD NLRP2 128236 and 130989 caused a sig-
nificant reduction of NLRP2 expression, as evidenced by
quantitative PCR and western blotting analysis (Figure 6A,
B). However, we did not observe significant morphological
changes in NLRP2 KD hESCs, or changes in the expression
levels (mRNA and protein) of pluripotency-associated
genes/markers (OCT4, NANOG, and SOX2) as compared
with control hESCs transfected with shLuc (Figure 6C,D);
these findings suggest that disruption of NLRP2 expression
in hESCs does not affect pluripotency maintenance.
Next, we examined whether reducing the expression
level of NLRP2 influences the in vitro differentiation of
hESCs. To this end, we subjected hESCs transfected with
or without KD NLRP2 to in vitro spontaneous differenti-
ation. Quantitative PCR analysis was used to demon-
strate that KD NLRP2 upregulated expression of genes
associated with trophoblastic lineages, but not other lin-
eages (Additional file 7), consistent with the spontaneousdifferentiation of iGRAs (Figure 4A). Moreover, treat-
ment of KD NLRP2 hESCs with specific trophoblastic
differentiation protocols resulted in higher expression of
trophoblast markers (CDX2, EOMES, ERR-β, and GCM1)
from differentiation day 2, and CGA and CGB at day 7, as
compared with control shLuc hESCs (Figure 7A). IF stain-
ing of representative KD NLRP2 hESCs (128236) also re-
vealed protein expression of GATA2, CDX2, EOMES,
CGA, and CGB at day 7 of trophoblastic differentiation
(Figure 7B). The percentage of cells double positive for
GATA2 and CDX2 was about twofold higher for differen-
tiated KD NLRP2 cells than for shLuc cells (29.4% vs.
15%) (Figure 7C). To further confirm that KD NLRP2
hESCs preferentially differentiate into trophoblasts, we
measured the amounts of placental hormones (human
chorionic gonadotropin, estradiol, and progesterone) in
the culture media. We found that concentrations of all
three hormones were markedly higher in the media from
either type of KD NLRP2 hESCs than in those of control
shLuc cells under conditions of trophoblastic differenti-
ation (Figure 7D). Together, these results demonstrate that
disruption of NLRP2 expression in hESCs results in a
biased differentiation propensity toward trophoblastic lin-
eages in differentiating hESCs.
Discussion
In this study, we demonstrate that iPSC clones can be
generated from human granulosa cells by retroviral
transduction of the four transcription factors: SOX2,
OCT4, c-MYC, and KLF4 [1]. The established iGRA
were similar to hESCs in several respects, including
Figure 4 (See legend on next page.)
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Figure 4 Comparison of the in vitro differentiation potential of human embryonic stem cell and induced pluripotent stem cell lines.
(A) Quantitative PCR analysis of genes related to three germ layers, germ cells, and trophoblasts in human embryonic stem cells (hESCs) and induced
pluripotent stem cells (iPSCs) following in vitro differentiation. The iPSCs (iCFB46, iCFB50, iGRA1, iGRA2, and iGRA7) and hESCs (H9) were examined
at day 20 of in vitro differentiation. Relative gene expression was first normalized to that of GAPDH, and then represented as the fold change
relative to H9. Values represent the mean ± standard deviation (SD) (n = 3). Statistical analysis for lineage-specific gene expression is presented
in Additional file 3. (B) Immunofluorescence staining against CDX2 and EOMES on day 7 of trophoblastic differentiation of representative H9,
iCFB50, and iGRA1 cells. Scale bars = 50 μm. (C) Quantitative analysis of CDX2 and EOMES positive cells from day 7 of trophoblastic differentiation of
H9, iCFB50, and iGRA1, iGRA2, and iGRA7. Approximately 600 cells were counted for each experiment. Values are means ± SD (n = 3). *P <0.05,
**P <0.01, ***P <0.001.
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and in vitro and in vivo differentiation propensity. More-
over, the microarray data indicate that the gene tran-
scriptional profiles of iGRAs were much closer to those
of hESCs than those of iPSCs derived from other paren-
tal sources, such as skin fibroblasts and dermal papilla
cells; on the other hand, the expression levels of the
NLRP2 gene and the tendency to spontaneously differ-
entiate toward trophoblastic lineages distinguished the
iGRAs from hESCs and iPSCs derived from fibroblastsFigure 5 Microarray-based analysis of global gene expression in mult
cell clones. (A) Hierarchical clustering of global expression profiles of hum
pluripotent stem cells (iPSCs) (iCFB46, iCFB50, iDPC3, iDPC4, iGRA1, and iGR
iPSCs (hESC to iCFB, hESC to iDPC, and hESC to iGRA). Each dot represents
lines, fourfold changes between two samples; purple arrow, low expression
map showing the expression levels of NLRP family members in hESCs, iPSC
microarray analysis to avoid sex bias between hESCs (H9 and NTU1 are botand dermal papilla cells. To confirm the existence of a
link between NLRP2 expression and trophoblastic differ-
entiation, we disrupted the expression of NLRP2 in H9
hESCs, and showed that such compromised NLRP2 ex-
pression resulted in enhanced trophoblastic differenti-
ation; this finding suggests that NLRP2 may play an
important role in modulating trophoblastic differenti-
ation in human pluripotent stem cells. Together, our re-
sults demonstrate that human granulosa cells are not
only suitable as a source for generating iPSCs, but mayiple human embryonic stem cell and induced pluripotent stem
an embryonic stem cells (hESCs) (H9 and NTU1) and induced
A2). (B) Scatter plots of relative gene expression between hESCs and
the averaged expression level of one gene in different samples. Green
level of the NLRP2 gene in iGRAs as compared with hESCs. (C) Heat
s, and their parental cells. Sex-related genes were excluded during
h 46, XX) and iPSCs.
Figure 6 Constitutive knockdown of NLRP2 in H9 human embryonic stem cells. (A) NLRP2 gene expression in shLuc (control) and
knockdown (KD) NLRP2 (128236, 130989, and 129801) H9 embryonic stem cells (ESCs), as determined by quantitative PCR. Values are mean ± standard
deviation (SD) (n = 3). *P <0.01. (B) NLRP2 protein expression in shLuc and KD NLRP2 (128236 and 130989) H9 ESCs before (ESC) and during
in vitro differentiation (days 10 (D10) and 20 (D20)), as determined by western blot. (C) Bright-field imaging and immunofluorescence staining
of KD NLRP2 H9 ESCs. Scale bar = 50 μm. (D) Expression of pluripotent genes in shLuc and KD NLRP2 (128236 and 130989) H9 ESCs by quantitative
PCR. Relative gene expression was first normalized to that of GAPDH, and then presented as the fold change relative to that in shLuc H9 ESCs. Values
are mean ± SD (n = 3).
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trophoblastic differentiation.
We have also demonstrated a new, alternative method
for deriving iPSCs from a limited number of parental
cells. If cells with different parental origins are mixed,
the parental identity of individual iPSC clones can be
distinguished by microsatellite assays. In the study de-
scribed here, we mixed granulosa cells from three individ-
uals, and were able to generate iGRAs from granulosa
cells of two different parental origins. However, the major-
ity of the analyzed iGRA lines were derived from one indi-
vidual (12 of 13 analyzed iPSC lines). Because efficient
iPSC generation involves many factors and complex
mechanisms, and because the granulosa cells derived from
different individuals were all subjected to the same repro-
gramming conditions in this experiment, we hypothesize
that the properties of the parental cell (in terms of genetic,
epigenetic, and/or cell growth) may influence iPSC repro-
gramming. One possible explanation for our finding is
thus that the granulosa cells from one individual pos-
sessed properties that enabled more efficient growth as
compared with those from the other two individuals.
Nevertheless, the demonstrated one-pot method for iPSC
derivation not only enables the simultaneous derivation of
iPSC lines from a small number of somatic cells frommultiple individuals, but also decreases the time and effort
required for such derivation.
Human granulosa cells have been reported to be mul-
tipotent in the presence of leukemia inhibitory factor
[12]. It also has been reported that certain granulosa
cells express OCT4 mRNA, which has been attributed
to their association with oocytes during gamete forma-
tion and maturation [20]. It is believed that oocytes con-
tain a powerful reprogramming factor, which enables the
totipotency reprogramming of differentiated somatic nu-
clei. This collection of unique characteristics has made
granulosa cells particularly suitable as a parental cell
population for somatic cell nuclear transfer in animals
[21]. Recently, Mao and colleagues also showed that
mouse iPSCs could be efficiently generated from granu-
losa cells using only Oct4 and Sox2 [22]. Therefore, it is
tempting to use granulosa cells as parental cells for effi-
cient hiPSC derivation. However, we found that the effi-
ciency of iGRA generation is not significantly higher
than that of foreskin-derived or follicle dermal papilla
cell-derived iPSCs, in terms of the numbers of either
early reprogramming colonies or reprogrammed iPSC
lines (Table 1). This may be explained by the fact that
our RT-PCR analysis did not detect OCT4 expression in
the granulosa cells used for iGRA derivation. Although
Figure 7 Trophoblastic differentiation of shLuc and knockdown NLRP2 (128236 and 130989) H9 embryonic stem cells. (A) Quantitative
PCR analysis of the indicated trophoblast markers at days 0 (embryonic stem cell (ESC)), 2, and 7 of differentiation. The relative gene expression
was first normalized to that of GAPDH, and then presented as the fold change relative to that in shLuc H9 ESCs. Values are mean ± standard
deviation (SD) (n = 3). (B) Immunofluorescence (IF) staining of trophoblast markers at day 7 of differentiation in 128236 knockdown (KD) NLRP2
human embryonic stem cells (hESCs). Scale bars = 50 μm. (C) Quantitative analysis of shLuc and 128236 KD NLRP2 hESCs that exhibited IF
staining for both GATA2 and CDX2 at day 7 of differentiation. About 500 to 600 cells were counted for each experiment. Values are mean ± SD
(n = 3). *P <0.05. (D) Immunoassays of three placental hormones (human chorionic gonadotropin (hCG), estradiol, and progesterone) at days 0, 2,
4, 6, 8, 10, and 14 of differentiation.
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other somatic cell-derived iPSCs, the microarray data indi-
cated that the global gene expression pattern of iGRAs
was much closer to that of hESCs (H9 and NTU1) than
those of other iPSC lines. Whether this phenomenon can
be attributed to the aforementioned unique characteristics
of granulosa cells will require further investigation.
We consistently observed that expression levels of the
NLRP2 gene are lower in iGRAs than in iPSCs derived
from other somatic cells, and that iGRAs have a ten-
dency to spontaneously differentiate toward a tropho-
blastic fate. NLRP2, a member of the NLRP (nucleotide-
binding oligomerization domain, leucine rich repeat and
pyrin domain containing) family, was recently shown to
be required for both human and mouse early embryonic
development [18,19]. In mice, KD of NLRP2 in oocytes
and zygotes dramatically compromised developmental
competence [18]. In addition, mutations of NLRP2 have
been discovered to associate with the human imprinting
disorder Beckwith–Wiedemann syndrome, which causes
fetal overgrowth; in addition, a second study suggested
an association between NLRP2 and recurrent miscar-
riages [23,24]. Since our granulosa parental cells were
obtained from patients undergoing infertility treatment,
there is a possibility that the granulosa cells carried gen-
etic or epigenetic defects in the NLRP2 gene, thereby
resulting in lower expression of NLRP2 in the iGRAs.
Failure to erase parental memory during iPSC repro-
gramming is also a possible reason for the low expres-
sion of NLRP2 in iGRAs.
NLRP family genes are well known for their role in
apoptosis and inflammation [25,26]; several members of
the NLRP family, including NLRP2, have been shown to
inhibit the nuclear factor (NF)-κB signaling pathway,
and function as a modulator of the inflammatory re-
sponse [27]. In mouse ESCs, increased expression of
NF-κB signaling has been implicated in ESC differenti-
ation [28,29], and it also has been demonstrated that
Nanog maintains mESC pluripotency through inhibition
of NF-κB activity [29]. The role of NF-κB signaling in
the maintenance of human pluripotency is still a matter
of debate. Augmentation of NF-κB signaling has been
suggested to maintain the undifferentiated status of hu-
man pluripotent stem cells [30,31]. However, Yang and
colleagues showed that an increase of canonical NF-κB
signaling was associated with differentiation of hESCs
[32]. Here, we show that KD of NLRP2 did not result in
either downregulation of NF-κB signaling or altered
pluripotency/differentiation of hESCs when compared
with wildtype hESCs (Additional file 8). Therefore, our
data support the hypothesis that NLRP2 may not dir-
ectly regulate pluripotency maintenance via NF-κB sig-
naling in hESCs. The role of NLRP2 in undifferentiated
hESCs, and how reduced expression of NLRP2 results inpreferential differentiation of hESCs toward the tropho-
blastic lineage, remain to be clarified.
Although there is currently no clear evidence implicat-
ing NLRP2 in trophoblast development, mutations of
NLRP7 have been reported to cause recurrent hydatidi-
form moles, an abnormality of pregnancy that is charac-
terized by hypertrophic vesicular trophoblasts in human
[33-35]. Recently, Mahadevan and colleagues demonstrated
that reduced expression of NLRP7 altered DNA methylation
and accelerated trophoblastic lineage differentiation in hESC
cultures [36]. Interesting, NLRP2 was found to possess a
similar function to that of NLRP7. No ortholog of human
NLRP7 is present in the mouse genome; rather, mouse
NLRP7 is believed to have arisen from mouse NLRP2 by a
gene duplication event [34,37]. Therefore, it is tempting to
suggest that NLRP2 and NLRP7 may share a redundant role
in regulating trophoblastic development, although the
mechanism by which NLRP2 regulates trophoblast devel-
opment is currently unknown.Conclusions
In summary, we have demonstrated a new method of
simultaneously generating iPSC clones from mixed gran-
ulosa cell populations derived from multiple individuals.
While the iGRAs resemble hESCs in several ways, their
NLRP2 expression levels were generally lower than those
of hESCs and iPSCs derived from other parental origins.
By comparing the differentiation potentials of iGRAs,
hESCS, and other iPSC lines, we found that iGRAs exhibit
preferential differentiation towards the trophoblastic lineage.
Importantly, KD of NLRP2 in hESCs also results in the pro-
motion of trophoblastic differentiation in vitro. Together,
these results suggest that NLRP2 may play a role in modu-
lating trophoblastic differentiation, although the mecha-
nisms involved require further elucidation.Additional files
Additional file 1: Primer sets used for (A) RT-PCR and (B)
quantitative PCR.
Additional file 2: Is a figure showing the microsatellite marker
analysis for human iGRAs.
Additional file 3: Is a table presenting a summary of the correlation
of gene expression in H9, iCFB46, iCFB50, and iGRA1, iGRA2 and
iGRA7. The relative gene expression of (A) mesoderm, (B) ectoderm, (C)
endoderm, (D) germ cells and (E) trophoblasts. P <0.05 labeled in red,
P <0.01 labeled in blue, P <0.001 labeled in purple.
Additional file 4: Is a figure showing the hierarchical clustering of
microarray-based gene expression profiles from multiple hESCs,
hiPSCs, and their parental cells. DPC, human follicle dermal papilla
cells; Fore, foreskin cells; Gra, granulosa cells.
Additional file 5: Is a figure showing the gene expression of NLRP2,
NLRP7, and NLRP12 in hESCs, iPSCs, and their corresponding
parental cells. (A) Expression patterns as determined using microarray
data. (B) Expression patterns as determined using quantitative PCR. The
relative gene expression levels were normalized to those in H9 hESCs.
Chuang et al. Stem Cell Research & Therapy  (2015) 6:14 Page 13 of 14Additional file 6: Is a figure showing the gene expression of NLRP2,
NLRP7, and NLRP12 before and during in vitro differentiation (day
20) in hESCs (H9 and NTU1) and iPSCs (iCFB10 and iCFB46, iDPC4
and iGRA1), as determined by RT-PCR. UD, undifferentiated hESCs or
iPSCs; D, differentiated hESCs or iPSCs; N, negative control for RT-PCR.
Additional file 7: Is a figure showing the quantitative PCR analysis
of genes related to pluripotency, germ layers (ectoderm,
mesoderm, and endoderm), germline, and trophoblast in in vitro
differentiated shLuc and KD NLRP2 (128236 and 130989) H9 ESCs at
days 10 and 20 of differentiation. Relative gene expression was first
normalized to that of GAPDH, and then presented as the fold change
relative to H9. Values are mean ± standard deviation (n = 3). Black line,
shLuc H9 ESCs; red line, KD NLRP2 (128236) H9 ESCs; green line, KD
NLRP2 (130989) H9 ESCs.
Additional file 8: Is a figure showing the quantitative PCR analysis
of genes related to NF-κB signaling in in vitro differentiated shLuc
and KD NLRP2 (128236 and 130989) H9 ESCs at days 10 and 20 of
differentiation. Relative gene expression was first normalized to
that of GAPDH, and then presented as the fold change relative to
shLuc H9 ESCs. Values are mean ± standard deviation (n = 3). ESC,
undifferentiated ESCs; RD10, in vitro random differentiation day 10; RD20,
in vitro random differentiation day 20. Black line, shLuc H9 ESCs; red line,
KD NLRP2 (128236) H9 ESCs; green line, KD NLRP2 (130989) H9 ESCs.
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